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ADCC: Antibody-Dependent Cell-mediated Cytotoxicity 
APC: Antigen Presenting Cells 
cDC: conventional (or myeloid) Dendritic Cell 
CXCL12/SDF-1: C-X-C motif chemokine ligand 12 / Stromal Derived Factor 1 
dNK: decidual Natural Killer cell 
FBS: Fetal Bovine Serum 
GM-CSF: Granulocyte-Macrophage Colony-Stimulating Factor 
hPB: Peripheral Blood derived from healthy donor 
HUVEC: Human Umbilical Vein Endothelial Cell 
ICS: Intracellular Cytokine Staining 
IFNγ: Interferon gamma 
IL-2: Interleukin 2 
IL-8: Interleukin 8 
IL-15: Interleukin 15 
ILC: Innate Lymphoid Cell 
iPB: Peripheral Blood derived from patient with a Pleural Effusion caused by 
inflammatory disease 
iPE: Pleural Effusion derived from patient with a Pleural Effusion caused by 
inflammatory disease 
K562: human erythroleukemia tumor cell line 
M1: Type 1 Macrophages 
M2: Type 2 Macrophages 
mAb: monoclonal Antibody 
M-CSF: Macrophage Colony-Stimulating Factor 




MHC: Major Histocompatibility Complex 
MMP: metalloproteinase 
NK: Natural Killer cell 
NSCLC: Non-Small Cell Lung Cancer 
OPN: Osteopontin 
PBS: Phosphate Buffered Saline 
pDC: plasmacytoid Dendritic Cell 
PFA: Paraformaldehyde 
PlGF: Placental Growth Factor 
PMA: Phorbol Myristate Acetate 
ptPB: Peripheral Blood derived from patient with a Pleural Effusion caused by primary 
tumor 
ptPE: Pleural Effusion derived from patient with a Pleural Effusion caused by primary 
tumor 
regDC: regulatory Dendritic Cell 
TAM: Tumor-Associated Macrophages 
TGFβ: Transforming Growth Factor beta 
Th1: T Helper 1 Lymphocytes 
Th2: T Helper 2 Lymphocytes 
tmPB: Peripheral Blood derived from patient with a Pleural Effusion caused by tumor 
metastasis 
tmPE: Pleural Effusion derived from patient with a Pleural Effusion caused by tumor 
metastasis 
TNFα: Tumor Necrosis Factor alpha 
Treg: Regulatory T Cell 
TUMIC: Tumor Microenvironment 





Natural Killer (NK) cells are lymphoid cells involved in tumor recognition and 
eradication. NK cell activity is impaired in cancer patients and in non-small cell lung 
cancer it has been shown that they acquire pro-angiogenic phenotype and functions 
similar to those of NK cells in the decidua. In this work, we characterized NK cells 
derived from inflammatory or malignant pleural effusions. 
We collected peripheral blood samples from healthy donors (hPB) and from patients 
with inflammatory (iPB) or malignant pleural effusions [from primary tumors (iPB) or 
tumor metastasis (tmPB) of different origins], in addition to inflammatory (iPE) and 
malignant pleural effusion fluids (ptPE and tmPE). We performed ex vivo FACS analysis 
of phenotype and cytokine production of PB and PE-derived NK cells, and analyzed 
cytotoxic NK cell function by using a CD107a NK cell degranulation assay against K562 
target cell line. In addition, we performed a 3-day culture with IL-2, IL-2 and TGFβ and 
with IL-2 in a conditioned media containing 33% of pleural fluid supernatant, to 
evaluate cytotoxicity of NK cells after treatment. We also isolated NK cells from buffy 
coats of healthy donors and cultured them for 7 days with IL-15 and with IL-15 with 
pleural fluid supernatant to evaluate polarization toward a pro-angiogenic phenotype 
caused by pleural effusion soluble factors. 
We found significantly increased levels of CD56bright CD16- NK cell in iPE (35%), ptPE 
(40%) and tmPE (60%) if compared with the PB of all samples analyzed (5%). PE-NK cells 
display an increased expression of CD49a decidual NK cell surface marker, are poorly 
mature (low expression of CD57) and yet activated (high expression CD69) and exhibit 
a deregulated expression of activating and inhibitory receptors. 
PE-NK cells display a higher amount of intracellular VEGF if compared to healthy and 




cells found in pleural effusions derived from patients with metastatic tumor (tmPE) 
induce formation of capillary-like structures in vitro. 
All patient’s NK cells analyzed showed a lower cytotoxicity ex vivo than hPB-NK cells.  
After 3-day culture with IL-2, NK cell cytotoxic function increased. Moreover, addition 
of TGFβ induced partial inhibition of cytotoxicity, whereas addition of PE supernatants 
resulted in total inhibition of cytotoxic function. 
NK cells Isolated from buffy coats from healthy donors, after 7-day culture with IL-15 + 
PE, increased CD56bright CD16- NK cell subset and VEGF production. Moreover, PE 
supernatants could induce a decreased production of IFNγ. 
Our data suggest a predominant role of tumor microenvironment in the NK cell 





IMMUNE SYSTEM AND TUMOR MICROENVIRONMENT 
The immune system can be considered a set of lymphoid organs, different cell types, 
humoral factors and cytokines. The ability to discriminate foreign pathogens and, at the 
same time, the tolerance to self-antigens is crucial for the achievement of homeostasis. 
The first line of host defenses consists in mechanical and chemical-physical barriers, 
after which participate the components of innate immunity that includes phagocytic 
cells (macrophages, neutrophils and dendritic cells), different types of immune and 
non-immune cells, which release inflammatory mediators, and Natural Killer cells. The 
main protagonists of the adaptive immunity are T lymphocytes, responsible for cellular 
immunity, and B cells, involved in humoral immunity. For a full and effective response, 
innate and adaptive mechanisms are interconnected into a sophisticated process of 
communication despite differences in the specificity and timing of activation [1, 2]. 
In the 19th century initial studies from most types of cancers showed the presence of 
inflammatory leukocytes in growing cancers and it was hypothesized that a relationship 
between chronic inflammation and cancer existed. Considering most types of cancer, 
infiltrating inflammatory cells may be different in terms of number and type of cells, 
however, this presence has long been interpreted as an attempt to interfere with tumor 
progression, termed "immune surveillance" [3]. It is demonstrated that there is a 
connection between a good patient prognosis and the presence of immune cell 
infiltrates [4, 5, 6, 7]. However, cellular and humoral responses that are generated in 
tissues because of infection by foreign pathogens, are stronger than those mediated by 
the tumor. Effectively, most tumor-associated antigens are considered "self" and non-




Recent studies have explained the mechanisms that connect inflammation and cancer: 
microbial infections, viral infections and autoimmune disease are considered promoter 
of chronic inflammation associated with cancer development [9]. Examples of 
pathologies implicated in this process are gastric cancer and gastric mucosal lymphoma 
caused by Helicobacter Pylori, hepatocellular carcinoma caused by hepatitis B or C virus 
and colon cancer correlated with inflammatory bowel disease [10]. Supporting the 
theory of the pro-tumor role of chronic inflammation there is the evidence that the 
treatment with nonsteroidal anti-inflammatory agents, such as cycloxygenase-2 (COX-
2) inhibitors, reduces the risk of developing colon and breast cancer and the related 
mortality [11]. 
It was documented that alterations in different classes of oncogenes and tumor-
suppressor genes lead to activate signaling pathways involved in inflammation. 
Examples are the tyrosine kinase RET, RAS, MYC and PTEN [12, 13, 14, 15]. 
Cancer-related inflammation can also activate transcription factors which are the key 
inducers of inflammatory mediators and contributes to tumor development promoting 
genomic instability, alteration in epigenetic events, enhancing proliferation and 
resistance to apoptosis of initiated cells, inducing tumor angiogenesis and tissue 
remodeling with consequent promotion of tumor cells invasion and metastasis [10]. 
Over the past three decades it has been possible to understand the function of immune 
cells in promoting tumor progression [16, 17]. Individuals subject to develop chronic 
inflammatory diseases show an increased risk of developing cancer [18]. Therefore, it 
was necessary to redefine the classical definition of carcinomas, extending it to the 
microenvironment in which most cellular components display immunosuppressive 
properties. Tumor cells not only try to escape from host defense mechanisms, but also 
acquire benefit from these conditions; cancer is also able to reprogram cells to create 
a favorable cell microenvironment to improve tumor progression [19]. 
The tumor microenvironment (TUMIC) generally includes, in addition to proliferating 
cells, a wide range of inflammatory and immune cells as well as stromal cells and 




stages [20]. The main TUMIC features are hypoxia, deregulated pH (approximately 6,7-
6,9 at the extracellular level and 7,4 in tumor cells), different metabolic state and a 
different vascular architecture that is usually fenestrated [21, 22]. 
It is important to emphasize that while normal blood vessels are lined by a single layer 
of interconnected endothelial cells, in the contest of TUMIC, endothelial cells are part 
of fenestrated vessels highly permeable for soluble blood components [23]. Tumor 
vessels are chaotically branched and display irregular diameters because of the 
compression of their walls by tumor and stromal cells [24, 25]. If the tumor growth 
exceeds over 1 mm, it requires a neo-vascularization to provide the right amount of 
oxygen and nutrients for proliferating cancer cells. However, during tumor expansion, 
the distances that must be covered by the vasculature increase and a localized hypoxia 
occurs [26, 27, 28]. A hypoxic environment is created very quickly during tumor 
development, resulting, in tumor cell, in an expression of genes that respond to hypoxia 
[29]; hypoxic stress plays a key role in regulating angiogenesis, and it is required for 
tumor invasive growth and metastasis formation [30]. This extremely heterogeneous 
realities, such as the tumor microenvironment, is enriched in immune cells-derived 
cytokines, chemokines and pro-angiogenic molecules, including: tumor necrosis factor 
α (TNFα), transforming growth factor β (TGFβ), vascular endothelial growth factor 
(VEGF), and Interleukin 1 (IL-1) and 6 (IL-6) [18]. The production of VEGF is a mechanism 
by which tumor infiltrating leukocytes increase angiogenesis and tumor development 
[31, 32]. The connection between angiogenesis induced by hypoxia and immune 
system tolerance has been studied and clarified [33, 34, 35]. The association between 
angiogenesis and immunosuppression may be justified in part by considering the 
immunosuppressive activity of angiogenic factors like VEGF, a cytokine secreted by 
most cancers [36, 37]. Hypoxic zones in the tumor can attract various immune cells in 
which the expression of hypoxia-induced transcription factors (HIF) is associated with 
the acquisition of a pro-angiogenic and immunosuppressive phenotype, such as Treg 




Therefore, the immune cells may directly or indirectly destroy cancer cells, but on the 
other hand can promote tumor growth and progression [1, 39]. This pro-tumor 
polarization was widely described in macrophages but it can also be extended to other 





Figure I. Within the tumor microenvironment, multiple cell types with established roles in 
immunosuppression have been shown to promote angiogenesis, through the production of 
various growth factors. Tumor cells, either in the steady state or in response to hypoxia, secrete 
soluble factors that recruit immunosuppressive cells to the tumor site. Recruited 
immunosuppressive cells include regulatory NK cells. The immunosuppressive cells secrete 
factors (such as VEGFA) that directly promote endothelial cell proliferation and migration, 
and/or induce the production of matrix metalloproteinases that act on the extracellular matrix, 
allowing for the development of new blood vessels. Pro-angiogenic growth factors derived from 
these cells probably promote angiogenesis in an additive or synergistic manner, together with 
tumor-derived VEGFA, transforming growth factor-β (TGFβ), adenosine, prostaglandin E2 
(PGE2), interleukin-6 (IL-6), reactive oxygen species (ROS) and oxidized lipids. Reprinted by 
permission from Macmillan Publishers Ltd: Nature Reviews Immunology. Motz GT, Coukos G. 
The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev 




IMMUNE SYSTEM CELLS: FEATURES AND POLARIZATION 
Macrophages 
Macrophages are immune cells recruited after tissue damage and inflammation, and 
they are professional phagocytes able to recognize and eliminate parasites and 
microorganisms. In fact, during bacterial infection, macrophages participate in the 
acute inflammatory response to eliminate invading pathogens; subsequently can 
remove tissue waste [42]. Macrophages are versatile cells with pleiotropic functions, 
even opposite: they can be immune-stimulatory and pro-inflammatory, or 
immunosuppressive and anti-inflammatory [42, 43]. Microenvironment stimuli can 
induce in macrophages different states of polarization [18]. 
Macrophages called M1, or classically activated, are stimulated by bacterial products 
(such as lipopolysaccharide, LPS) and cytokines produced by T helper 1 (Th1) 
lymphocytes. They also produce pro-inflammatory cytokines, they can mediate 
pathogens elimination and to kill cancer cells. Generally, they have an IL-23high, IL-
10low, IL-12high phenotype and are also able to produce reactive oxygen species and 
nitric oxide [42, 44]. On the other hand, M2 macrophages are polarized in T helper 2 
(Th2) lymphocyte-rich microenvironments, i.e. in the presence of cytokines such as 
interleukin 4 (IL-4) and 13 (IL-13) [43, 45]. M2 macrophages also promote tissue 
remodeling and angiogenesis [9, 46, 47], and suppress adaptive immune responses. 
Both M1 and M2 macrophages could be recruited in cancers microenvironment such 
as monocytes because of chemokines produced by tumor cells and stromal cells, but 
they can also migrate from adjacent tissues [9]. 
Tumor-associated macrophages (TAMs) are derived from peripheral blood monocytes 
that are recruited in tumor mass thanks to growth factors like VEGF, chemokines 
including CCL2 and molecules involved in CXCL12/SDF-1/CXCR4 signaling pathway [9, 




the presence of the macrophage colony-stimulating factor (M-CSF) produced by 
neoplastic cells [50, 51]. 
TAMs show pro-tumor features: they can induce neo-angiogenesis, to promote 
secretion of soluble factors that support cancer cell resistance to apoptotic stimuli and 
to stimulate malignant cells proliferation and invasion. Tumor-associated macrophages 
have also been associated with direct suppression of adaptive immunity by producing 
interleukin 10 (IL-10) and TGFβ that suppress Th1 lymphocytes; producing chemokines 
such as CCL17, CCL18 and CCL22 which are attractive for Th2-type cells that lack of 
cytotoxic activity and for T regulatory cells (Treg) [52]. Under hypoxic conditions, that 
is a common characteristic of solid tumors in vivo, proangiogenic factors are produced 
by TAMs, including: VEGF, epidermal growth factor (EGF), some members of the family 
of fibroblast growth factors (FGF) which are able to stimulate the recruitment and the 
migration of endothelial cells (EC), platelet-derived growth factor (PDGF), also 
implicated in the recruitment of pericytes, the CXC angiogenic chemokines, (CXCL8/IL-
8 and CXCL12/SDF-1), thymidine phosphorylase and TGFβ [9, 49]. Because of hypoxia 
there is an up-regulation of the pro-tumor cytokine TNFα, [53], of the 
immunosuppressive cytokine IL-10 and of arginase [54]. The cytokines produced by 
TAMs can also act indirectly on angiogenesis by autocrine stimulation [55]. The 
molecular profile of TAMs is characterized by a defective NF-kB and by an inability to 
up-regulate interleukin 12 (IL-12) and other inflammatory cytokines following 
inflammation [56]. In addition to producing VEGF, tumor-associated macrophages are 
also influenced by this angiogenic factor: they produce the receptor VEGFR1 [57] and 
respond to it by migrating and modulating their biological activity [58, 59]. Cancer cells 
take advantage of the degradation of the extracellular matrix by macrophages and they 
can perform local invasion, penetrate the blood vessels and spread and give rise to 
metastasis [60]. Basement membrane and extracellular matrix components 
degradation is the result of the release of proteases including different matrix 
metalloproteinases (MMPs 1, 2, 3, 9, and 12), as well as plasmin and urokinase. These 




and proliferation of endothelial cells [9, 49, 61]. Interestingly, it has been shown that a 
subset of TAMs may also counteract tumor growth using a nonspecific cytotoxicity 
activity based on phagocytosis and on cancer cell lysis mediated by factors such as IL-
12 and granulocyte-macrophage colony-stimulating factor (GM-CSF) [62]. A crucial 
target for anti-angiogenic therapy could be represented by TEMs (Tie2 expressing 
macrophages), a subset of TAMs associated with the construction of the pre-metastatic 
niche, whose deletion inhibits angiogenesis and tumor growth [63, 64, 65]. 
From circulating monocytes, derived from the bone marrow, originate tissue-resident 
and inflammatory macrophages [66]. In the same way, TAMs are derived from 
circulating monocytes or tissue-resident macrophages [67]. Macrophage mobilization 
into tumor tissues is regulated by multiple microenvironmental signals such as 
cytokines, chemokines, extracellular matrix components, and hypoxia. Hypoxic areas 
release higher amount of chemoattractants such as VEGF-A, endothelin and EMAPII 
that enhance macrophage migration to these hypoxic sites. Hypoxia also imprisons 
macrophages by decreasing their mobility through the upregulation of MKP-1 enzymes; 
this terminates the macrophage response to chemoattractants outside the hypoxic 
areas [68]. There is evidence that both tissue-resident and recruited macrophages may 
cohabit in tumors and it was demonstrated that TAMs in a murine mammary tumor 
model are phenotypically and functionally distinct from mammary tissue-resident 
macrophages and that recruited macrophages may differentiate and form most TAMs 
[69] 
Neutrophils 
In the context of circulating white blood cells, the polymorphonuclear leukocytes 
neutrophils are the most abundant cell population. Foreign microorganisms, captured 
through phagocytosis, are eliminated by lytic enzymes and anti-microbial molecules 
contained in their cytoplasmic granules. Neutrophils are involved in the early stages of 




to features described for macrophages, neutrophils are sensitive to microenvironment 
stimuli and modify their behavior, often in diametrically opposed directions, in 
response to paracrine and endocrine received signals. Different subsets of neutrophils 
with distinct profiles of cytokine production and surface markers have been described 
[70, 71]. 
The neutrophil mechanisms of action consist in degranulation leading the release of 
lytic enzymes and the production of ROS with antimicrobial potential (O2-, H2O2, HOCl) 
[72]. Neutrophils are also able to secrete various cytokines such as TNFα, IL-1β, IL-1Rα, 
IL-12 and VEGF and chemokines such as CXCL1, CXCL8/IL-8, CXCL9, CXCL10, CCL3 and 
CCL4 [73, 74] directly involved in tissues remodeling and angiogenesis. For example, 
CXCL1/macrophage inflammatory protein-2 (MIP-2) leads to recruitment of neutrophils 
that, in turn, release biologically active VEGF-A, resulting in angiogenesis in vivo [75]. 
However, neutrophils are also able of produce a wide range of anti-cancer and anti-
angiogenic molecules. Upon stimulation with pro-inflammatory stimuli, neutrophils 
have enzymatic activities that, in vitro, generate biologically active angiostatin-like 
fragments. Because angiostatin is a potent inhibitor of angiogenesis, tumor growth, and 
metastasis, the data suggest that activated neutrophils not only act as potent effectors 
of inflammation, but might also play a critical role in the inhibition of angiogenesis in 
inflammatory diseases and tumors, by generation of a potent anti-angiogenic molecule 
[76]. 
The pro-angiogenic and anti-angiogenic activities of neutrophils, and their role in tissue 
destruction or reconstruction, suggest that there are different subsets of neutrophils, 
characterized by different activities: anti-tumorigenic N1 neutrophils were found to be 
associated with direct tumor cell killing as well as activation of CD8+ T cells and pro-
tumorigenic N2 neutrophils were also detected [77]. 
Tumor-associated neutrophils (TANs) were found in a variety of tumors (such as colon 
adenocarcinoma, melanoma and gastric carcinoma) suggesting a potential role in 
tumor progression and angiogenesis (78). In fact, these cells can promote, for example, 




remodel the extra cellular matrix and TNFα to induce neutrophil degranulation, in 
addition to VEGF, CXCL8/IL-8 and CXCL1 release [80, 81]. 
Dendritic cells 
The third phagocytic cells of the immune system are dendritic cells (DCs) that are 
present constitutively in the epithelia of most tissues, as well as in blood and in 
lymphoid organs. DCs, on the basis of location and morphology, play a critical role in 
the identification and the stimulation of both innate and acquired immune effector 
responses that lead to elimination of invading pathogens. Dendritic cells can act as 
"sentinels" that, once recognized microbial antigens, are able to migrate in secondary 
lymphoid organs, to process the foreign antigens and to present peptide epitopes to 
naïve T cells, acting as potent antigen presenting cells (APCs) [82]. APC function and 
maturation of dendritic cells are promoted by some angiostatic molecules, including 
the thrombospondin-1 [83] and CXCL4 [84] and CXCL14 chemokines [85]. Moreover, 
dendritic cells are located at the interface between innate and acquired immunity and 
for this reason they can establish a crosstalk with NK cells [86] and with neutrophils 
[87]. 
Dendritic cell population includes two main cell types: conventional or myeloid 
dendritic cells (cDCs) and the plasmacytoid DCs (pDCs) [88]. The cDC subset secretes 
primarily IL-12, while the pDC releases the anti-angiogenic cytokine interferon-alpha 
(IFNα) [89, 90]; in addition, mature cDCs are able to inhibit angiogenesis releasing 
angiostatic chemokines (CXCL9, CXCL10 and CCL21) [91]. 
A third subset of dendritic cells, regulatory dendritic cells (regDCs), is characterized by 
immune-suppressive features. regDC polarization is promoted by soluble factors such 
as VEGF, IL-6 and TGFβ, that can contribute to the reduction of mature DCs, to the 
expansion and accumulation of immature and tolerant DCs and to the possible DCs 
polarization into a pro-tumor phenotype promoting Th2 or Treg responses [92, 93]. DCs 




[96, 97], which can also function as angiogenic factors. Other cytokines released from 
DCs and that influence angiogenesis are IL-6 and TGFβ [98]. 
Different soluble tumor-derived factors, such as VEGF (99), adenosine [100], 
prostaglandin E2 (PGE2) [101] and TGFβ [102], are crucial for activation, migration of 
endothelial cell, and for inhibition of DC function that involves suppression of T cells 
and development of Treg cells. The VEGF-dependent DC inhibition is mediated by 
VEGFR1 receptor expressed on immature DC [103, 104]. Dendritic cells are also able to 
secrete different pro-angiogenic chemokines, such as CXCL1, CXCL2, CXCL3, CXCL5, 
CXCL8/IL-8 and CCL2 [105, 106]. 
Myeloid-derived suppressor cells 
Myeloid-derived suppressor cells (MDSCs) include immature macrophages or 
granulocytes and myeloid dendritic cell progenitors with high plasticity in their 
immune-suppressive function. However, these myeloid progenitors may differentiate 
in vitro into mature macrophages, granulocytes or even dendritic cells depending on 
available cytokines [107]. Two main subsets are described: granulocytic MDSCs and 
monocytic MDSCs [108, 109]. MDSCs can produce IL-10 and TGFβ, cytokines involved 
in the generation of tolerogenic DCs (110) and Treg cells [111, 112]. 
Recruitment and expansion of MDSCs may result from high levels of GM-CSF and IL-1β 
cytokines in case of chronic inflammation and in some cancer types the link between 
inflammation and cancer progression has been established [113, 114]. The involvement 
of myeloid-derived suppressor cells in inhibiting antitumor immunity is also reinforced 
by the ability to impair Natural Killer cells activity [115, 116], and to down-modulate 
recirculation of both naïve CD4+ and CD8+ T cells [117]. MDSC’s function is also 
involved in the angiogenesis process through the release of soluble factors such as 
MMP9 and VEGF, and thanks to the possibility of direct differentiation of these cells 





T and B lymphocytes 
The thymus-derived T-cells are divided into two main subpopulations based on the 
expression of CD4 or CD8 surface protein. In blood and secondary lymphoid organs, 60-
70% of T cells are CD4+ and 30-40% are CD8+ [2]. CD4+ T lymphocytes, also named T 
helper cells, can activate both cellular and humoral immune responses and they can 
recognize peptides presented by MHC Class II molecules. Depending on functions and 
cytokines produced, Th cells can be divided into three major subgroups [119]. The IL-
12 cytokine produced by macrophages or dendritic cells promotes the differentiation 
of Th1 lymphocytes; these cells express T-box transcription factor and produce 
interleukin 2 (IL-2) and interferon gamma (IFNγ). The IL-4 cytokine produced principally 
by NK-T and mast cells, induces differentiation of Th2-lymphocytes, expressing the 
GATA3 transcription factor and producing IL-4, IL-5, IL-9, IL-13 and GM-CSF. Finally, 
TGFβ and IL-6 allow differentiation of Th17 cells that produce IL-6 and IL-17 [2]. 
CD8+ T cells are cytotoxic cells (CTLs) that lyse cells through recognition of foreign or 
mutated antigens bound to MHC Class I molecules, as often happens for intracellular 
pathogens and for tumor cells. 
Instead Treg cells are characterized by CD25 and CD4 surface molecule co-expression 
and by nuclear transcription factor Foxp3 expression that is essential to their 
development. The regulatory activity of these cells is mainly due to the secretion of 
immunomodulatory cytokines, such as IL-10 and TGFβ [120]. Under physiological 
conditions Treg cells have a beneficial role in preventing autoimmunity [121]. However, 
in the presence of a tumor, they can expand and migrate into tumor site, to down-
regulate the proliferation of effector T cells and to suppress anti-cancer strategy of T 
helper cells and cytotoxic T cells [122, 123]. CCL22 and CCL28, which produced within 
the TUMIC, allows the selective recruitment of Treg cells who start to express in a 
constitutive manner the neuropilin-1 co-receptor [124] and are involved in the process 




T cells are conditioned to acquire a regulatory T cells features with CD8+ CD28- 
phenotype [126, 127]. 
A subpopulation of T-lymphocytes consists in NKT cells, that are a relatively newly 
recognized member of the immune community, with profound effects on the rest of 
the immune system despite their small numbers. They are true T cells with a T cell 
receptor (TCR), but unlike conventional T cells that detect peptide antigens presented 
by conventional major histocompatibility (MHC) molecules, NKT cells recognize lipid 
antigens presented by CD1d, a non-classical MHC molecule. NKT cells are CD4- CD8- 
and could have immune-regulatory function through releasing a large amount of 
cytokines, including IL-4, IFNγ, and TNF [128, 129]. 
B cells constitute about 15% of peripheral blood leukocytes and can differentiate into 
plasma cells and, once activated, they produce antibodies against pathogens [130]. The 
primary immune role of B cells is to produce antibodies, but they can also influence T 
cell function via antigen presentation and, in some contexts, immune regulation. In 
many human cancers, the presence of tumor-infiltrating B cells and tumor-reactive 
antibodies correlates with extended patient survival [131, 132, 133, 134]. On the other 
hand, T cell responses can be adversely affected by B cell production of 
immunoregulatory cytokines [135, 136, 137]. The isotype and concentration of tumor-
reactive antibodies may also influence tumor progression. Recruitment of B cells into 
tumors may directly reflect the subtype and strength of the anti-tumor T cell response. 
As the response becomes chronic, B cells may attenuate T cell responses to decrease 
host damage, similar to their described role in chronic infection and autoimmunity 
[138]. 
Innate Lymphoid Cells (ILCs) and Natural Killer cells 
Innate lymphoid cells (ILCs) represent a family of different innate lymphocytes that, 
different from T and B lymphocytes, lack recombinant activating genes (RAG-1 or RAG-




grouped in three major subsets based on their phenotypic and functional features as 
well as of their dependency on given transcription factors. Briefly, ILC-1 are dependent 
on T-bet transcription factor and produce interferon IFNγ. Group 2 ILCs (ILC-2) express 
GATA-3 transcription factor and produce IL-4, IL-5 and IL-13 (Type 2) cytokines, while 
group 3 ILCs (ILC-3) express RORγt transcription factor and produce IL-17 and IL-22. 
Natural Killer cells represent the prototypical member of the ILC-1 family [139, 140]. 
Natural Killer cells 
Natural Killer cells are large granular lymphocytes with the ability to lyse various types 
of cancer cells and virus-infected cells in the absence of a previous activation [141]. NK 
cells constitute the 5-15% of circulating lymphocytes [142, 143], however this 
proportion may vary with age of subject [144, 145]. In blood, the turnover of human 
Natural Killer cells is about two weeks [146] in accordance with data found in mouse 
models [147]. However, they are also found in tissues such as the spleen, lungs, kidney 
and liver, as well as in uterus and in slighter amounts in lymph nodes [148, 149, 150, 
151]. 
Upon priming by various soluble factors (for example, IL-15, type I IFN, IL-12, IL-18), NK 
cells boost the maturation and activation of DCs, macrophages and T cells, through a 
combination of cell surface receptors and cytokines. Conversely, NK cells can also kill 
immature DCs, activated CD4+ T cells and hyperactivated macrophages. These NK cell 
regulatory functions are kept in check by the recognition of constitutively expressed 
self-molecules (for example, MHC class Ia and MHC class Ib molecules) by means of 
inhibitory receptors (for example, the inhibitory KIR and the CD94-NKG2A complex), as 
is represented in Figure II [152]. 
Natural Killer cells are involved in the crosstalk of DCs; certain NK cell subsets could 
eliminate immature DCs, while others promote DC maturation, which in turn could 
induce further activation of NK cells (86); the functions of these innate immune cells 





Figure II. Regulation of immune responses by NK cells. Reprinted by permission from Macmillan 
Publishers Ltd: Nature Immunology. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. 
Functions of Natural Killer cells. Nat Immunol. 2008 May; 9(5):503-10, copyright 2008. [152]. 
– NK cell activation 
Concerning NK cell activation, the main functional hypothesis is related to the "missing 
self" mechanism (Figure IIIb), since NK cells can detect and lyse cells lacking expression 
of MHC-I molecules [153]. In 1990, several studies showed the presence of activator 
and inhibitor surface receptors expressed by NK cells [154], identifying a new 
recognition model called "induced-self" (Figure IIIc) [155], that complements the 
previous hypothesis of "missing-self". NK cells are also able to exert Antibody-
Dependent Cell-mediated Cytotoxicity (ADCC), a mechanism of cell-mediated immune 
defense, whereby an effector cell of the immune system actively lyses a target cell, 







Figure III. a. Balance of signals delivered by activating and inhibitory receptors regulates the 
recognition of healthy cells by NK cells. b. Tumor cells that down-regulate major 
histocompatibility complex (MHC) class I molecules are detected as 'missing self' and are lysed 
by NK cells. c. Tumor cells can overexpress induced stress ligands recognized by activating NK 
cell receptors, which override the inhibitory signals and elicit target cell lysis. d. Tumor antigen-
specific antibodies bind to CD16 and elicit antibody-dependent NK cell-mediated cytotoxicity. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Cancer. Morvan MG, 
Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2016 
Jan;16(1):7-19, copyright 2016. [156]. 
The NK cell ability to recognize their target is the result of a complex balance between 
inhibitory and activatory signals and require not only the lack of MHC-I expression on 
target cells membrane but also the expression of ligands able to trigger activating 
receptors [157]. The first checkpoint is the lack of MHC-I molecules expression [153, 
158]: their down-regulation is observed during cell transformation [159] or viral 
infection and this phenomenon prevents the binding of NK cells inhibitory receptors to 





Thus, NK cells can recognize and destroy a wide range of abnormal cells (including 
cancer cells and virus-infected cells, cells bound by antibodies and allogeneic cells, as 
well as stressed cells), without damaging healthy cells and normal self-cells [161]. 
– NK cell subsets 
There are several distinct subsets of human Natural Killer cells classified by CD56 
surface molecule expression: the main peripheral blood subset consists of the NK cells 
with low density of CD56 expression (CD56dim) and with high levels of the CD16 
(CD16+, the Fc-γ receptor) and represent the 90-95% of NK cells in the blood. These 
cells kill their targets by releasing cytolytic granules containing perforin and granzyme, 
and can secrete only precociously high levels of cytokines [162]. In vitro interaction with 
cancer cells results in the production of IFNγ by these innate lymphoid cells [163]. The 
remaining 5-10% of peripheral blood NK cells are poorly cytotoxic, display lower 
amounts of perforin [149], but can produce large amounts of cytokines, including IFNγ, 
TNFα, and GM-CSF, and they show a higher surface density of CD56 (CD56bright) and 
reduced or negative expression of CD16 (CD16low/-). In vitro exposure to specific 
cytokines, such as IL-2, IL-12 and/or IL-15, induce these cells to acquire a cytotoxic 
CD56dim CD16+ phenotype with strong killing capacity [164, 165]. CD56high CD16− NK 
cells are thought to be immature precursors of CD56low CD16+ mature NK cells [142], 
although some studies have suggested that the two are separate lineages [143]. 
At the level of the decidua [166] (the hormone-responsive glandular layer of 
endometrium that sloughs off at each menstrual flow (decidua menstrualis) or at the 
termination of pregnancy) a third subset of NK cells was found, and called decidual 
Natural Killer cells (dNK). This subpopulation is characterized by a CD56superbright 
CD16- phenotype and can release significant amounts of pro-angiogenic factors, 
especially VEGF, placental growth factor (PlGF) and interleukin 8 (IL-8). They are 
necessary for the formation of the spiral arteries during endometrial differentiation 




implantation of the embryo to avoid non-self-rejection. Compared to the two subtypes 
found in peripheral blood, dNK cells display specific surface markers, in particular CD9 




– NK cell receptors 
Among the most important activating receptors there are NKp30, NKp44 and NKp46, 
normally named "natural cytotoxicity receptors" (NCRs) [169], member of the C-type 
lectins family NKG2D, 2B4, NTBA, CD69, NKp80 and DNAM-1, as it is shown in Figure IV, 
together with the most representative human NK cell receptors. 
 
Figure IV. NK cell activation programs result from the integration of multiple activating and 
inhibitory signals. Inhibitory receptors are in blue; 2B4, which can act as an activating or an 
inhibitory molecule, is in grey; other receptors are in green. Reprinted by permission from 
Macmillan Publishers Ltd: Nature Immunology. Vivier E, Tomasello E, Baratin M, Walzer T, 





Another important molecule is the CD16 receptor (Fc-γ-RIIIA) that mediates recognition 
of the Fc portion of IgG1 and IgG3 antibodies allowing the identification and the attack 
of opsonized target cells through antibody-dependent cell-mediated cytotoxicity 
mechanism (ADCC). Many activating receptors are characterized by a common 
structural motif in the cytoplasm, called ITAM (Immunoreceptor Tyrosine-based 
Activation Motif) [170]. 
Specific inhibitory receptors for MHC Class I molecules include KIRs (Killer 
immunoglobulin-like receptors) in humans, the lectin-like dimers Ly49 in mice, and the 
lectin-like heterodimers CD94-NKG2A in both species [171, 172]. A conserved 
peculiarity in these inhibitory receptors is the presence of one or two intra-cytoplasmic 
inhibitors domains called ITIMs (Immunoreceptor Tyrosine-based Inhibition Motifs) 
that promote the signal transduction pathway maintained both in human and mouse 
[173]. Interacting with MHC Class I molecules, constitutively expressed by most healthy 
cells in conditions of "dynamic equilibrium" but that might be lost because of cellular 
stress, viral infection or neoplastic transformation, the inhibitory receptors enable NK 
cells to be educated to recognize the "missing-self" and, at the same time, tolerate self-
antigens [174]. However, there are also other inhibitory receptors, including 
p75/AIRM1 and IRP60, which can recognize molecules outside the family of MHC Class 
I molecules [175]. 
– NK cell killing strategies 
The target elimination by NK cells can be performed through three main strategies. The 
first mechanism, shared by T cytotoxic lymphocytes, is faster and more effective to kill 
cells and consists in releasing perforin and granzymes (including the granzyme B) that 
are stored in secretory granules [176]. This strategy is implemented either when 
activatory signals exceed inhibitory signals, or because of ADCC. When Natural Killer 
cells are activated, the granule exocytosis leads to the release of these molecules 




homopolymers and creating a hole that facilitates the entry of granzyme in the cell 
cytoplasm. These serine-proteases act on different target molecules, proteins of the 
family of caspases, that induce programmed cell death (apoptosis). This leads to 
chromatin condensation, membrane blebbing and nuclear DNA fragmentation [177, 
178]. The whole process is strictly regulated: there are the formation of an 
"immunological synapse", at the point of contact between Natural Killer cell and the 
target cell, and there is a rearrangement of the actin cytoskeleton; then NK cell 
microtubular organizing center and secretory lysosomes polarize toward the 
immunological synapse. At this point the secretory lysosomes are anchored to the 
plasma membrane, and then merge with it and release their cytotoxic molecules [179]. 
Alternatively, there is a slower mechanism that requires the expression of tumor 
necrosis factor ligand superfamily (FasL/TNF) on the NK cell surface and a Fas death 
receptor on target cell [180]. An intracellular region, called death domain, characterizes 
these receptors that recruit an adaptive protein through homophilic interactions, which 
is required for cytotoxic signal transduction [181]. This initiates the start of enzymatic 
caspase cascade leading to apoptosis. 
Finally, Natural Killer cells can produce IFNγ a cytokine that inhibits cancer cell 
proliferation in vitro and tumor growth in vivo by inducing the anti-angiogenic CXCL10 
chemokine [182]. IFNγ is also able to potentiate the NK cells cytotoxicity inducing an 
over-expression of adhesion molecules or an increase of cancer cells susceptibility to 
cytotoxicity mediated by the release of granules or by death receptor [183]. In addition, 
the IFNγ produced by Natural Killer cells plays an important role in the production of 
IL-12 by dendritic cells [184]. In this way, NK cells contribute indirectly at the tumor 
control starting and maintaining a T cells-mediated effective antitumor response 




– NK cells and angiogenesis 
Physiological angiogenesis is a complex process finely controlled by numerous pro-
angiogenic cytokines as well as inhibitory factors. Therefore, to induce angiogenesis, 
the balance between pro and anti-angiogenic factors near tumor should lean in favor 
of angiogenic stimuli, either through down-regulation of angiogenesis inhibitors or up-
regulation of pro-angiogenic cytokines [186]. 
The most important inducer of angiogenesis is vascular endothelial growth factor that 
is part of a gene family that contains 5 related genes (VEGF-A also known as VEGF, 
VEGF-B, VEGF-C, VEGF-D and PlGF) that are regulators of angiogenesis, lympho-
angiogenesis or both. Probably this is the most important inducer of angiogenesis 
[187]. Specifically, hypoxia regulates the production of VEGF via transcription factor 
HIF-1α, which also promotes invasiveness by transcriptional activation of the met 
protooncogene [188]. HIF-1α levels are regulated by prolyl hydroxylase whose activity 
is directly related to the availability of oxygen [189, 190]. The central regions of solid 
tumors become hypoxic when the tumor grows, thereby VEGF is produced and 
consequently the tumor angiogenesis induction occurs [191]. VEGF acts by binding and 
activating tyrosine kinase receptors VEGFR-1 and VEGFR-2 [192, 193]. It has been 
shown that activation of these receptors contributes to angiogenesis since antibodies 
that inhibit their function also inhibit tumor development [194]. 
Angiogenesis is also induced by CXC chemokines, such as IL-8 and CXCL12/SDF-1 (C-X-
C motif chemokine ligand 12 / Stromal Derived Factor 1). The IL-8 was originally 
discovered as a pro-angiogenic factor derived from macrophages [195]. Some 
microvascular endothelial cells express CXCR1 and CXCR2 receptors which are activated 
by IL-8 that induce changes in the cytoskeleton organization, causing cell movement 
and contributing to increased permeability observed in tumor-associated blood vessels 
[196]. In addition, IL-8 receptors on endothelial cells promote proliferation and 
angiogenesis induction. IL-8 also increases the production of MMP2 and MMP9 




has an important role in the induction of angiogenesis. In fact, various data indicates 
that the increase in the expression level of IL-8 in various tumors is associated with 
increased malignancy and ability to metastasize [199, 200]. The neutrophil role is 
essential in the response to IL-8, responding to this chemokine through CXCR2 
chemokine receptor agonists. IL-8 induces intense angiogenic reactions in vivo, but no 
angiogenic response to these factors was observed in neutropenic mice, demonstrating 
an essential role for neutrophils [201]. 
CXCL12/SDF-1 is a potent chemoattractant molecule for resting lymphocytes, 
monocytes and CD34+ hematopoietic progenitor cells [202, 203]. Only CXCL12/SDF-1 
binds to CXCR4 receptor, which has only this chemokine known as a ligand [204]. It has 
been reported that CXCL12/SDF-1 recruits bone marrow-derived endothelial cells 
precursors to neo-forming blood vessels [205, 206], thus antibodies directed against 
CXCL12/SDF-1 inhibit angiogenesis [207]. Moreover, CXCL12/SDF-1 stimulates tumor 
progression through direct effects on CXCR4+ cancer cells, and it has been observed a 
direct correlation between poor prognosis and CXCR4 presence on cancer cells in 
different types of malignancies [208, 209]. 
Osteopontin (OPN) is a glycoprotein containing arginine, glycine, aspartate (RGD) and 
exists as a component of the extracellular matrix and immobilized as a soluble pro-
inflammatory cytokine [210, 211]; it is also able to play important roles in tissue 
remodeling, fibrosis (210) and angiogenesis [212]. Many of these effects are mediated 
by OPN binding to Integrin αvβ3 or CD44 receptors [213]. 
– NK cells and cancer 
Studies conducted in both human and mice have helped us to understand that Natural 
Killer cells play an important role in immune defense against solid cancers and 
hematological tumors [214, 215, 216, 217]. Nevertheless, as emerged from functional 
analysis, the cytotoxic activity of tumor infiltrating NK cells (TINKs) is often modulated 




other immune cells, Natural Killer cells may also infiltrate the tumor mass. The TUMIC 
can affect NK cell functionality through a variety of cytokines and soluble factors, both 
inhibiting their cytotoxic function and promoting a pro-neoplastic/pro-angiogenic 
phenotype [221]. 
Among various solid tumors, lung cancer is the leading cause of cancer-related 
mortality in men. About 80% of all lung cancers are non-small cell lung cancer (NSCLC) 
that can be divided at the phenotypic level into two main sub-types: squamous cell 
carcinoma (SCC) and adenocarcinoma (ADC). Interestingly, lung tissues are particularly 
enriched in Natural Killer cells [222, 223]. 
Natural Killer cell infiltrating NSCLC were characterized predominantly by CD56bright 
CD16- subtype. Moreover, these cells show reduced perforin production if compared 
to autologous peripheral blood NK cells. In addition, based on the expression of CD107a 
surface marker, they display reduced cytotoxic capacity following incubation with 
human erythroleukemic cell line K562 in vitro [216, 224]. 
CD56+ CD16- dNK cells are able to produce pro-angiogenic factors [225] and NSCLC NK 
cells have the ability to produce proangiogenic factors like VEGF, PlGF and IL-8 [226] A 
further demonstration of the angiogenic potential of these cells was obtained by 
testing ex vivo the chemotactic capacity of NK cell-derived supernatants on human 
umbilical vein endothelial cells (HUVECs). Furthermore, it has been observed that the 
supernatants of tumor infiltrating NK cells can induce a capillary-like organization of 
HUVECs in vitro. It has also been reported that an in vitro exposure to the 
immunosuppressive cytokine TGFβ induces NK cells from peripheral blood of healthy 
donors to produce angiogenic factors such as VEGF and PlGF, suggesting that this 
cytokine is involved in the TINK angiogenic switch [226]. This has been added to 
previous knowledge concerning the ability of TGFβ, very often present in solid tumor 
microenvironment, to polarize the cytotoxic CD56dim CD16+ NK cell subset into a 
CD56bright CD16- phenotype with some characteristic similarity to dNK cells [227, 228]. 




of malignancies, related to pleural effusions (PA) caused by primary or metastatic 
pleura tumors [219, 229]. 
INFLAMMATORY AND NEOPLASTIC PLEURAL EFFUSIONS 
The pleura is a thin membrane that consists of five layers: an external fibro elastic layer, 
an under-pleural highly vascularized layer of loose connective tissue, an elastic surface 
layer tissue, a submesothelial layer of loose connective tissue and finally a mesothelium 
layer. The pleura directly adjacent to the lungs is the visceral pleura, the pleura in 
contact with the rib cage and diaphragm is the parietal pleura. Once fully developed, 
the pleural space typically contains 0,5-2,0 ml of pleural fluid that allows the parietal 
and visceral pleura to slide over each other during breathing. The pleural fluid, which 
normally has a similar composition to plasma with a lower concentration of proteins (< 
1,5 g/dl), is derived from the capillaries and exits from the parietal pleural pore and 
from the lymphatic vessels. The multipotent mesothelial layer located into the pleural 
space, is very active concerning metabolism, along with humoral and cellular immune 
components that also plays an active role in the production and absorption of pleural 
fluid [230]. 
The abnormal fluid accumulation in the pleural space, because of an imbalance 
between excessive production and absorption, can lead to a medical condition known 
as pleural effusion [231]. Pleural lesions could generate from a neoplastic or 
inflammatory conditions. About the first aspect, the pleura can be the site of primary 
tumors, such as mesothelioma, or secondary tumors. Secondary metastatic 
involvement is more common than primary tumors. Approximately 50% of patients 
with metastatic cancer develop a malignant pleural effusion. At the epidemiological 
level, more than 75% of all cases of malignant pleural effusion are caused by lung, 
breast, ovary cancers or lymphomas [232]. In males, the main cause of cancer 
development is lung cancer, while in females the most common cause is breast cancer 




effusion that often contains cancer cells. In general, the presence of pleural fluid is 
accompanied by poor prognosis and the survival for patients with metastatic cancer 
that develop a malignant pleural effusion is around three months [235]. 
Other causes of pleural effusions are: inflammation secondary to viral or bacterial 
infection with pleural localization; pleural inflammation in presence of tuberculosis; 
extension to the pleura, by contiguity, of lung inflammation (pneumonitis) developed 
into a portion of the lung near the pleural surface (metapneumonic pleurisy); and 
finally, this can be a pleural manifestation of autoimmune disease [231]. 
The mechanisms involving the pleural fluid accumulation include: increase of interstitial 
fluid in the lungs as a result of increased pulmonary capillary pressure (such as heart 
failure) or permeability (e.g. pneumonia); decreased intrapleural pressure (such as 
atelectasis, the absence of ventilation of pulmonary alveoli); decreased oncotic 
pressure of plasma (for example hypoalbuminemia); increase in pleural membrane 
permeability and lymphatic flow obstructed (e.g. pleural neoplasm or infection) or 
rupture of the thoracic duct (for example chylothorax). An important distinction is the 
fact that the pleural effusion may be unilateral or bilateral; it can also occupy the large 
pleural cavity or be localized to a circumscribed pleural space portion [236, 237]. 
There are two types pleural effusions based on biochemical characteristics of the fluid: 
transudative PE and exudative PE. The transudative PEs are the result of an imbalance 
between hydrostatic and oncotic forces and are caused by a limited number of medical 
conditions such as heart failure and cirrhosis; less common causes include nephrotic 
syndrome, atelectasis, peritoneal dialysis, constrictive pericarditis and superior vena 
cava obstruction. In contrast, the exudative PE occurs when there is an alteration of 
local factors that influence the accumulation of pleural fluid that induces an excessive 
liquid production. Causes of this second type of plural effusion may be cancer or 
inflammatory processes [238]. 
In 2013, Vacca P. et al. have demonstrated that a preponderance of NK cells in 
malignant pleural effusions display a CD56bright CD16low phenotype, in contrast with 




regulated and inhibitory receptors are not up-regulated, contrary to what happens for 
TINK in solid tumors. Functionally, it is found that these cells, according with their own 
phenotype, quickly produce large amounts of cytokines, such as IFNγ and TNFα, 
following short-term stimulation with IL-2. An important aspect that has emerged 
following in vitro IL-2 treatment for 72 hours is the rapid and efficient cytotoxic ability 
against classical cancer target cells such as K562. The fact that Natural Killer cells 
examined are not anergic but actively functional was explained as the result of the fact 
that, at the pleural effusion level, NK cells are not in contact with cancer cells. 
Therefore, the cytokines and tumor-derived inhibitory factors may be diluted and do 
not reach the adequate concentration to demonstrate an inhibitory effect. The authors 
suggest that their findings could have relevant impact concerning in vivo therapeutic 
treatment for patients with primary or metastatic pleural tumors. NK cells cytotoxic 
activity in vivo may be induced or reinforced through local infusions of IL-2. Another 
possibility would be to expand and activate Natural Killer cells in vitro with IL-2 before 
their reintroduction into the patient. 
Analyzing pleural effusion soluble factors, it was demonstrated that malignant PEs were 
found to have 77-fold higher VEGF-A levels compared to inflammatory PEs in addition 
with elevated levels of pro-angiogenic factors VEGF-A, CXCL4 and MMP-8, and low 
levels of pro-inflammatory cytokines IL-8, MCP-1, and TGFβ1 in malignant PEs [239]. In 
another work, in contrast, it was found that the amount of TGFβ was high in malignant 
PE. All these molecules have a relevant role in the polarization of immune system cells 
and could influence also Natural Killer cell functions [240]. 
These results are very promising and have been the basis for the realization of this 
project of thesis, for which in addition to malignant pleural effusion was considered 
another medical condition, i.e. the inflammatory pleural effusion. 
AIMS OF THE STUDY 
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AIMS OF THE STUDY 
It is extensively demonstrated that the tumor microenvironment (TUMIC) plays a major 
role in cancer and in tumor progression. Different cell types are present in the TUMIC, 
such as the malignant-transformed cells (that acquire tumor-promoting functions 
during carcinogenesis), the stromal cells, the endothelial cells and a wide assortment 
of immune cells [55]. 
Immune cells infiltrating tumors typically show a tumor-induced polarization 
associated with attenuation of antitumor functions and generation of pro-tumor 
activities, among these the induction of angiogenesis. The immune cells better 
characterized are macrophages, neutrophils, dendritic cells and the myeloid-derived 
suppressor cells. Recently, also Natural Killer cells obtain the scientist attention and it 
was demonstrated that a subset of these cells could contribute, in NSCLC, in the 
promotion of angiogenesis during cancer [226]. 
The current investigation aims to determine whether NK cells residing in pleural 
effusion derived from patients with inflammatory diseases, primary or metastatic 
tumors of various origins, are characterized by decidual features and pro-angiogenic 
and pro-tumor characteristics, similar to those found in NSCLC. 
It was already demonstrated that IL-2 treatment can promote the restoration of 
cytotoxicity in NK cells from patients with pleural effusions and our goal is to evaluate 
if IL-2 could be counteracted by TGFβ, often present in TUMIC, or directly by pleural 
effusion soluble factors. 
The aim of this work is also to evaluate if molecules contained in pleural effusion fluids 
can induce a switch in healthy NK cells phenotype and functions. We think that a better 
characterization of Pleural Effusion NK cells may lead in the future to an appropriate 
therapy able to improve NK cell cytotoxic function contrasting with tumor progression 
and the angiogensis associated phenomenon. 
PATIENTS, MATERIALS AND METHODS  
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PATIENTS, MATERIALS AND METHODS 
PATIENT SELECTION 
Subjects included in this study were healthy donors and patients with pleural effusions 
caused by inflammatory disease or primary or metastatic tumors of different origin. 
Healthy Controls (h): n=14 (M: n=8; F: n=6); age: mean±SEM=58,1±3,4 (Table 1A). 
Inflammatory Pleural Effusions (iPE): n=18 (M: n=16; F: n=2); age: mean±SEM=72,2±2,2 
(Table 1B). Malignant Pleural Effusions from Primary Tumors (ptPE): n=18 (M: n=9; F: 
n=9); age: mean±SEM=72,8±2,5 (Table 1C). Malignant Pleural Effusions from Tumor 
Metastasis (tmPE): n=27 (M: n=11; F: n=16); age: mean±SEM=68,7±2,4 (Table 1D). 
Samples analyzed include peripheral blood of healthy subjects (hPB) and patients with 
inflammatory pathologies (iPB), primary tumors (ptPB) or tumor metastasis (tmPB) and 
the respective pleural effusions: iPE, ptPE and tmPE, respectively. All the experiments 
were performed on fresh samples. 
Patients with diabetes, human immunodeficiency virus (HIV)/hepatitis C virus 
(HCV)/hepatitis B virus (HBV) infection, overt chronic inflammatory conditions, 
previously treated with chemotherapy or radiotherapy, or those iatrogenically 
immunosuppressed or having undergone myeloablative therapies were excluded. 
All samples were collected from healthy donors and patients at the Ospedale di Circolo 
of Varese, following informed consent, with local Ethics Committee approval. 
NK CELL PHENOTYPE ANALYSIS 
Total mononuclear cell suspension derived from peripheral blood and pleural effusion 
samples was obtained by ficoll hystopaque (LONZA, Basel, Switzerland) gradient 
stratification. To identify NK cell subsets, cells obtained were subsequently stained with 
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monoclonal antibodies against surface markers (CD14-PE and CD45-FITC, CD3-PerCP, 
CD56-APC, CD16-FITC, CD9-PE, CD49a-PE, CD57-PE, CD69-PE, NKp30-PE, NKG2D-PE and 
NKG2A-PE) all purchased from Miltenyi Biotech (Auburn, CA). After 10 minutes fixation 
with PFA 1% in PBS, samples were stored at 4°C until a BD FACS Canto II analysis was 
conducted. Briefly, after physical parameters analysis (FSC/SSC), CD45+ CD14- 
lymphocytes were gated and assessed for NK cell markers. NK cells were gated on 
CD45+ CD3- CD56+ total lymphocytes. 
EVALUATION OF NK CELL CYTOKINE PRODUCTION 
NK cells were subjected to intracellular cytokine staining (ICS) assay after 1h incubation 
with monensin (2 mM, BD), or, to evaluate the production of IFNγ, after an overnight 
stimulation with PMA (10 ng/ml, Sigma-Aldrich, St Louis, MO) and Ionomycin (500 
ng/ml, Sigma-Aldrich) plus monensin (2 mM, BD). Briefly, following staining with anti-
human mAbs CD3-PerCP, CD56-APC, CD16-FITC (Miltenyi Biotec), cells were 
permeabilized and fixed using the Cytofix/Cytoperm fixation kit (BD), according to the 
manufacture instructions and finally stained with different anti-cytokine PE-conjugated 
mAbs (VEGF, CXCL12/SDF-1, perforin, osteopontin, IL-8 and IFNγ, Miltenyi Biotec) and 
analyzed with a BD FACS Canto II. 
MORPHOGENESIS OF HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS 
The capacity to induce formation of capillary-like networks by endothelial cells seeded 
on matrigel (BD) was tested using HUVECs at the concentration of 20x103 cells/well in 
a 96-well plate. Negative and positive controls (CTRL- and CTRL+) were obtained using 
a serum-free medium and a medium containing 10% of FBS, respectively [226]. 
HUVECs were resuspended in 0,2 ml of a medium containing pleural fluids (1/3 of the 
medium) and transferred to the matrigel-coated wells for 6-hour incubation. 
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HUVECs were resuspended in 0,2 ml of a medium containing or containing NK cell 
supernatants (protein concentration: 15 µg/µl) and transferred to the matrigel-coated 
wells for 6-hour incubation). NK cell supernatants were obtained with the procedure 
described below: NK cells were purified from peripheral blood and pleural effusion 
samples using two steps of MicroBeads-coated with mAbs: CD3 MicroBeads (Miltenyi 
Biotec): CD3 positive cells were eliminated and the CD3- fraction was purified using 
CD56 MicroBeads (Miltenyi Biotec) to isolate CD3-/CD56+ NK cells. Purified NK cells 
were incubated 6 hours in serum-free RPMI medium. Supernatants were collected; 
residual cells and debris were discarded by centrifugation and supernatants were 
concentrated with Concentricon devices (Millipore, Temecula, CA) with a 5-kDa 
membrane pore cutoff. 
The morphologic organization was documented with an inverted microscope (Zeiss) 
and angiogenesis was evaluated with ImageJ software and an Angiogenesis Analyzer 
Tool. 
EVALUATION OF NK CELL CYTOTOXICITY 
The NK cell degranulation activity assay was assessed on total mononuclear cells from 
PB and PE after in vitro 4h incubation with the human erythroleukemia K562 tumor cell 
line target in presence of anti-CD107a mAb (Miltenyi Biotec) and monensin (2 mM, BD) 
at a NK cell:Target ratio of 1:1. Cells were then stained with anti-CD3 and anti-CD56 
mAbs (Miltenyi Biotec), fixed for 10 minutes with PFA 1% in PBS and stored at 4°C until 
BD FACS Canto II analysis. This assay was performed on fresh PB of healthy donors and 
on fresh PB and PE of patients with iPE, ptPE and tmPE; ex vivo and after a 3-day cell 
culture with IL-2 (100 U/ml), IL-2 plus TGFβ (10 ng/ml) (Miltenyi Biotec) and IL-2 in a 
culture medium containing 33% of cell-free supernatants from iPE, ptPE or tmPE. Cell-
free supernatants were obtained after pleural fluids centrifugation at 300xg for 15 
minutes. Concentrations of IL-2 and TGFβ were used according to the protocol of Bruno 
et al. [226]. Viability of NK cells incubated with culture media with 33% of PE 
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supernatants was evaluated counting NK cells in Burker Chamber using Trypan Blue 
reagent. 
POLARIZATION OF NK CELLS FROM HEALTHY DONORS WITH PE SUPERNATANTS 
NK cells from 13 buffy coats were isolated with Kit RosetteSep (StemCell Technologies), 
according to the protocol of the manufacturer. Briefly, after ficoll separation, 
mononuclear cells and Red Blood Cells (RBC) are incubated in proportion 1:100 with 
RosetteSep kit in the concentration of 50 µl/ml (reaction volume: 50x106 mononuclear 
cell/ml). After 20 minutes of incubation at room temperature the suspension was 
stratified on ficoll to obtain purified NK cells that were isolated through negative 
selection procedure. The conditioning of the purified NK cells with supernatant of 
pleural effusion was performed to determine whether the supernatant could polarize 
NK cells towards a pro-angiogenic phenotype. NK cells purified from each buffy coat 
are cultured for 7 days in RPMI medium 2x106 NK cells/ml, with 10% of FBS, 1% of 
Penicillin/Streptomycin and IL-15 (10 ng/ml) or IL-15 in a culture medium containing 
33% of iPE, ptPE or tmPE supernatants.  
Concentration of IL-15 and culture timing are based on the protocol of Cerdeira and 
colleagues [241]. Each kind of PE supernatant used was a pool of 10 supernatants 
derived from 10 different patients. During incubation, every two days, 33% of culture 
media containing PE was removed and replaced by fresh PE and IL-15 was added to the 
culture media of all samples. Viability of NK cells incubated with culture media with 
33% of PE supernatants was evaluated every two days counting NK cells in Burker 
Chamber using Trypan Blue reagent. 
EVALUATION OF IN VITRO-CONDITIONED NK CELL CYTOKINE PRODUCTION 
After 7-day culture, NK cells were subjected to ICS assay after 1h incubation with 
monensin (2 mM, BD), or, to evaluate the production of INFγ, after an overnight 
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stimulation with PMA (10 ng/ml, Sigma-Aldrich, St Louis, MO) and ionomycin (500 
ng/ml, Sigma-Aldrich) plus monensin (2 mM, BD). Briefly, following staining with anti-
human mAbs CD3-PerCP, CD56-APC, CD16-FITC (Miltenyi Biotec), cells were 
permeabilized/fixed using the Cytofix/Cytoperm fixation kit (BD), according to the 
manufacture instructions and finally stained with different anti-cytokine antibodies and 
analyzed with a BD FACS Canto II. PE-conjugated mAbs (VEGF, CXCL12/SDF-1, IFNγ, 
perforin, osteopontin and IL-8) were all from Miltenyi Biotec. 
FLOW CYTOMETRY ANALYSES 
Flow cytometric analyses were performed using BD FACS Canto II and BD FACSDiva 
Software (v8.0.1). 
STATISTICAL ANALYSES 
Statistical analyses were performed using the GraphPad Prism statistics and graphing 
program (GraphPad Software, San Diego, CA). One-way ANOVA with Bonferroni post-






NK CELLS ISOLATED FROM MALIGNANT PLEURAL EFFUSION ARE ENRICHED IN 
CD56BRIGHT CD16- NK CELLS 
It was demonstrated that there is an unbalanced distribution of CD56bright CD16- NK 
cell subsets between peripheral blood of healthy subjects (h), peripheral blood of 
patient with inflammatory (iPB) and malignant pleural effusions (ptPB and tmPB) and 
their respective pleural effusion samples (iPE, ptPE and tmPE): the percentages of 
CD56bright CD16- NK cells are higher in all PE samples, as shown in the representative 
dot plots (Figure 1). 
The analysis of the phenotype performed by flow cytometry demonstrated that the NK 
cell percentage found in all samples analyzed were very similar with healthy controls 
(about 10% to 20% of total lymphocytes) as reported in Figure 2A. It is however 
interesting to consider that the volume of starting material of peripheral blood samples 
and pleural effusions is very different: to analyze PB-NK cells we used 15 ml of 
peripheral blood while, for PE-NK cells, pleural effusion volume varies from 1 to 2 liters, 
hence the number of NK cells obtained from the latter was higher and this situation 
allows us to performed more experiments with a single sample. 
Regarding the two major subpopulations of NK cells it was demonstrated that the 
percentage of NK cells represented by CD56bright CD16- subset is increased in all 
pleural effusions analyzed if compared with autologous peripheral blood samples and 
PB of healthy donors (iPE=35%; ptPE: 40%; tmPE=60%) (Figure 2B). In Figures 2C-D are 




NK CELLS FROM PLEURAL EFFUSIONS SHOW AN INCREASED EXPRESSION OF THE DECIDUAL 
NK CELL MARKER CD49A 
Evaluating the presence of surface markers, typical of dNK cells, such as CD9 and CD49a, 
it was observed a partial decidual differentiation of Natural Killer cells isolated from 
inflammatory and malignant pleural effusions. 
Regarding CD9 we did not find differences in CD9+ NK cells percentage between all 
samples analyzed (Figure 3A) and the Mean Fluorescence Intensity parameter (MFI) 
was not statistically significant (Figure 3B). 
CD49a analysis reveals that the percentage of CD49a+ NK cells found in pleural effusion 
(especially in ptPE and in tmPE) are significantly higher if compared to PB-NK cell 
samples (Figure 3C). The same trend could be noticed in the analysis of MFI: the value 
is higher for NK cells derived from ptPE and tmPE if related to hPB and autologous ptPB 
and tmPB (Figure 3D). 
Therefore, in all types of pleural effusion there was observed an augmented percentage 
of CD49a+ Natural Killer cells, but not that of CD9+, revealing the acquisition of a partial 
decidual-like phenotype. Decidual NK cells are characterized by pro-angiogenic 
features and could help tumor growth. On the other hand, within inflammatory context 
these data could be interpreted in a positive manner: the growth of new blood vessels 
may be the preferred way to recruit other immune cells needed to maintain the 
inflammatory process. 
PLEURAL EFFUSION NK CELLS ARE PREDOMINANTLY IMMATURE AND HIGHLY ACTIVATED 
The differentiation molecule CD57, which identifies mature Natural Killer cells with a 
potent cytotoxic potential but a decreased sensitivity to cytokines and a reduced 
replicative ability [242], was examined. The NK cell percentage that displays this marker 




statistically significant differences (Figure 4A). The same trend was noticed in the MFI 
parameter analysis (Figure 4B). Poorly mature Natural Killer cells can be interpreted in 
a twofold manner: there may be cells that have not completed the maturation process 
or they may be fully differentiated NK cells de-differentiated because of stimulation of 
the microenvironment. 
We have also analyzed the percentage of CD56bright CD57+ NK cells, showing that 
mature CD56bright NK cells were very low in this specific subset: CD56bright CD57+ NK 
cells were about 20% in ptPB and 1% in ptPE and 10% in tmPB and 0,5% in tmPE (data 
not shown). 
We have observed a partial activation of Natural Killer cells: a high percentage of NK 
cells display CD69 surface molecule, a marker of NK cell early activation and present 
also on decidual NK cells [243]. We have demonstrated that CD69 is up-regulated on 
the NK cell membrane in pleural effusion samples, predominantly in those derived from 
neoplastic patients (Figure 4C). NK cells positive for this marker display a higher density 
expression of CD69 molecule on their surface if compared with PB samples, especially 
in ptPB/PE, as it is represented in the MFI graph (Figure 4D). 
Thus, in the context of inflammatory and neoplastic pleural effusions, Natural Killer 
cells are mainly immature but partially activated. 
INHIBITORY AND ACTIVATING RECEPTOR EXPRESSION ON NK CELLS FROM PLEURAL 
EFFUSIONS ARE NOT DEREGULATED 
Natural Killer cell activation is the result of a sophisticated detection system based on 
the balance between signals transduced by activating receptors, including natural 
cytotoxic receptors (NKp30, NKp44, NKp46) and NKG2D, and inhibitory receptors such 
as NKG2A. Regarding NKp30 and NKG2D surface receptor we did not observe relevant 
differences between all samples (Figures 5A-B). We have also evaluated the percentage 
of NK cells positive for NKG2A, an inhibitory receptor of NK cells, which seems to be 




are not statistically significant and it is necessary to evaluate more samples. The signals 
from the microenvironment in which Natural Killer cells are located did not affect the 
expression of the membrane proteins analyzed. It will be interesting to examine the 
expression of other NK cell receptors. 
EVALUATION OF CYTOKINE PRODUCTION: VEGF-PRODUCING NK CELLS ARE INCREASED 
IN PLEURAL EFFUSIONS 
We have focused our attention on NK cell spontaneous cytokine production, angiogenic 
potential and cytotoxic function. NK cells can secrete cytokines capable of stimulating, 
guiding and influencing the other immune system cell types responses. In the present 
study, we investigated Natural Killer cell ability to produce some pro-angiogenic 
cytokines, including VEGF, CXCL12/SDF-1, osteopontin, IL-8 and the pro-inflammatory 
molecule IFNγ. Our data suggest that NK cells derived from pleural effusions can 
produce the pro-angiogenic cytokine VEGF: there is a trend for an increase in 
percentage of VEGF+ NK cells in all PE analyzed if compared to NK cells derived from 
autologous peripheral blood and healthy donors peripheral blood. Statistically 
significant was only the difference between hPB and tmPE (Figure 6A). 
We studied the production by NK cells of CXCL12/SDF-1 that in tumors is demonstrated 
to be a pro-tumor molecule and found no significant differences (Figure 6B). These data 
seem to exclude CXCL12/SDF-1 as a determinant factor playing a role in the pro-tumor 
and pro-angiogenic process in the neoplastic pleural effusion disease. Osteopontin+, IL-
8+ and IFNγ+ NK cells percentages do not display any differences between samples 




PLEURAL EFFUSION FLUIDS FUNCTIONALLY PROMOTE ANGIOGENESIS-ASSOCIATED 
EFFECTS ON ENDOTHELIAL CELLS 
We evaluated the ability of pleural effusions fluid from patients with inflammatory 
disease, primary tumor or tumor metastasis, to induce capillary like structure formation 
in vitro. The assay revealed that all pleural effusion fluid analyzed contains pro-
angiogenic molecules able to promote morphogenic effect on HUVECs, like it is 
represented in Figure 7. In Figure 7A capillary like network structures formed by 
HUVECs can be seen. Parameter analyzed with ImageJ software and Angiogenesis Tool 
(Figure 7B) display that iPE and ptPE angiogenic properties are like those in positive 
controls (CTRL+) and that tmPE have the highest proangiogenic potential, confirming 
the hypothesis that tmPE could be associated with the most pro-angiogenic tumor 
microenvironment. 
NK CELLS FROM TMPE CAN INDUCE CAPILLARY LIKE STRUCTURES FORMATION IN VITRO 
We evaluated the ability of NK cells derived from peripheral blood and pleural effusions 
from patients with inflammatory disease, primary tumor or tumor metastasis, to 
secrete pro-angiogenic molecules that can induce capillary-like structure formation in 
vitro (Figure 8). 
NK cells from patients with inflammatory pathologies or primary tumors, both from 
peripheral blood and from pleural effusions, are not able to induce angiogenesis on 
HUVECs. On the contrary, capillary-like structure formation is significant in the case of 
NK cells isolated from tmPE, demonstrating that a more pro-angiogenic TUMIC can 




THE PERCENTAGE OF CYTOTOXIC PERFORIN+ NK CELLS IS STRONGLY DIMINISHED IN 
PLEURAL EFFUSIONS 
Another crucial characteristic in Natural Killer cell biology is represented by their 
spontaneous cytotoxic capacity culminating in the induction of an apoptotic process in 
their cellular targets. A hallmark of NK cell activation, and especially of CD56dim CD16+ 
NK cells, is the degranulation against target cells, that consist in the releasing of lytic 
granules containing perforin and granzymes [162]. Therefore, for these set of 
experiments we have considered the CD56dim CD16+ NK cell subset, known to be the 
most cytotoxic, to better individuate differences between measured samples. 
Analyzing NK cells able to produce perforin and consequently to exert their cytotoxic 
functions we have found a decreased percentage of CD56dim CD16+ perforin+ NK cells 
in all pleural effusions considered (Figure 9A). Interesting, MFI data also suggest that 
CD56dim CD16+ NK cells from all patient samples can produce a lower amount of 
perforin if compared to healthy controls peripheral blood (Figure 9B), suggesting a 
systemic effect on a crucial NK cell function. In both inflammatory and malignant 
pleural effusion, the percentage of CD56dim CD16+ perforin-producing NK cells was 
diminished in as compared to controls. 
NK CELLS FROM PLEURAL EFFUSIONS SHOW LOWER CYTOTOXICITY EX VIVO 
The cytotoxic potential of NK cells, which is the result of the involvement of activating 
and inhibitory receptors expressed on the membrane surface, was examined in a 
twofold manner: considering directly the production of perforin and evaluating the 
exposure, following activation, of the membrane glycoprotein CD107a on the NK cells 
surface. 
We have evaluated the NK cell cytotoxic potential against a classical target, K562 cell 




Natural Killer cells as they lack the MHC class I complex, required to inhibit NK activity. 
The degranulation assay underline the presence of CD107a surface marker, which 
presence on NK cell membrane correlate with granules exocytosis, is strictly associated 
with cytotoxicity. CD107a surface exposure is a marker of degranulation and NK cell 
cytotoxicity [244], as well as CD8+ T cell [245] and CD4+ T cells cytotoxicity [246]. 
We have analyzed the CD56dim CD16+ NK cell subset, characterized by a cytotoxic 
potential. CD56dim CD16+ NK cells response is weak in both peripheral blood and 
malignant pleural effusions from patients, on day zero ex vivo, compared to CD56dim 
CD16+ NK cells from peripheral blood of healthy donors and the same trend occurs also 
evaluating MFI (Figures 10A-B). 
In conclusion, the functional assays conducted in this work showed a diminished 
percentage of CD56dim CD16+ Natural Killer cells expressing CD107a marker, 
measured ex vivo, in all types of pleural effusions and peripheral blood of patients if 
compared with CD56dim CD16+ NK cells from healthy subjects. 
IL-2-TREATEMENT INCREASE CYTOTOXICITY OF PLEURAL EFFUSION-DERIVED NK CELLS 
BUT IT IS PARTIALLY INHIBITED BY TGFΒ AND, MORE STRONGLY, BY AUTOLOGOUS 
PLEURAL FLUID 
As reported in the literature, among the most important cytokines known for their 
ability to activate NK cell functions there are the interleukins IL-2, IL-12 and IL-15. 
Specifically, IL-2 and IL-15 induce proliferation and reinforce cytotoxicity of Natural 
Killer cells, while the IL-12 alone increases the cytolytic activity but has a modest 
proliferative effect [247]. The binding of each of these cytokines to their respective 
receptors activates various intracellular kinase signaling pathways [248, 247, 249]. 
In this study, we wanted to understand whether the 3-day in vitro stimulation with the 
exogenous cytokine IL-2 could make changes in the cytolytic potential of Natural Killer 




We investigated NK cell cytotoxicity on the most cytotoxic NK cell subset, CD56dim 
CD16+, after 3-day in vitro stimulation with IL-2, IL-2+TGFβ and IL-2+autologous PE, to 
evaluate if TGFβ, often present in tumor microenvironment, or other soluble factors 
residing in pleural effusion could cause a loss of function of IL-2 treatment. 
In NK cells from all pleural effusions analyzed, the NK cell effector function increased 
considerably because of the presence of IL-2 in the culture medium (Figures 11A-B-C). 
The observation of this reaction may suggest that the CD56dim CD16+ Natural Killer 
cells in pleural effusions are not fully inhibited: probably within the pleural fluid 
compartment Natural Killer cells do not show a feature completely compromised for 
the dilution of immunosuppressive factors and for the lack of close contact with tumor 
cells or with suppressor cells associated with the tumor. 
Hence, the ability of pleural effusion Natural Killer cells to respond quickly to IL-2 in 
vitro, suggests the possibility to induce or enhance the antitumor effects of NK cells by 
local intra-pleural administration of this cytokine or by a re-infusion of NK cells derived 
from pleural effusions and activated with IL-2 ex vivo [274]. As reported in the 
literature, also in the case of renal cell carcinoma it was found that intra-tumor NK cells 
could lyse target cells only after in vitro stimulation with IL-2 [250]. 
For the better understanding of the behavior of Natural Killer cells in the TUMIC we 
have conditioned NK cells with a typical cytokine often found in the tumor 
microenvironment: TGFβ. We know that in cancer, TGFβ acts as a "Janus-like" cytokine: 
in the early stage of tumor formation, it acts as a tumor suppressor, inhibiting the 
replication of cancer cells and promoting apoptosis. On the contrary, in the later stages 
of tumor progression, TGFβ exercises a pro-tumor role, promoting cell survival, 
epithelial-mesenchymal transition and tissue invasion, as well as acting in the tumor 
microenvironment as an immuno-suppressive and angiogenic agent [251, 252]. After 
stimulation with IL-2, at day 3, the degranulation activity was increased in CD56dim 
CD16+ NK cells from all patient’s samples but the addition of TGFβ at the medium 




The CD56dim CD16+ NK cells cytotoxicity after 3-day culture with IL-2 plus pleural 
effusion supernatants are very like those revealed ex vivo suggesting that the action of 
IL-2 in vivo could be counteracted by soluble factors present in the fluid 
microenvironment. Interestingly, NK cells that respond stronger to IL-2 treatment are 
CD56dim CD16+ NK cells derived from patients with metastatic tumors (Figure 11C). In 
Figure 11D are shown CD56dim CD16+ CD107a+ NK cells from healthy subjects, ex vivo 
and after 3-day treatment with IL-2 or IL-2 plus iPE, ptPE and tmPE. Cytotoxic CD56dim 
CD16+ NK cells percentage remains high (about 40%) also after IL-2 treatment and 
diminishes in presence of TGFβ and, mostly, in the culture conditions with all types of 
pleural effusion supernatants (Figure 11D). These data necessarily lead to think that the 
examined pleural effusion supernatants may contain various soluble factors capable of 
deregulate and then inhibit the cytotoxic potential of Natural Killer cells. 
NK CELLS OF HEALTHY DONORS CONDITIONED WITH PLEURAL EFFUSION SUPERNATANTS 
ACQUIRE PARTIAL DECIDUAL-LIKE FEATURES 
The presence in the pleural effusions of factors that can promote a pro-angiogenic 
phenotype of Natural Killer cells was examined through a polarization of NK cells 
purified from buffy coat of healthy volunteers. We have examined phenotype and 
cytokines/chemokines production by NK cells isolated from buffy coat and conditioned 
for 7 days with IL-15 or IL-15 with 33% of pleural effusion supernatant (IL-15, IL-15+iPE, 
IL-15+ptPE and IL-15+tmPE). 
Regarding the CD56bright CD16- NK cell subset we found that supernatants of both 
malignant pleural effusions can induce an expansion of this population (Figure 12A). 
Also, total CD56bright NK cells and CD16- NK cells display the same behavior trend 
(Figures 12B-C). 
Moreover, we have analyzed the production of pro-angiogenic factors, such as VEGF, 
CXCL12/SDF-1, osteopontin and IL-8. We have demonstrated that there is a trend of 




containing malignant pleural effusion supernatants (Figure 13A). Regarding 
CXCL12/SDF-1+ NK cells, they are present in lower percentage in the condition with IL-
15+ptPE and tmPE if compared to other conditions, reflecting what we have already 
discovered for NK cells ex vivo (Figure 13B). The percentages of osteopontin+ and IL8+ 
NK cells do not display differences between samples analyzed (data not shown) 
Finally, we have evaluated the IFNγ pro-inflammatory and anti-tumor cytokine 
production after 7-day treatment: interestingly, we found that all pleural effusion 
supernatants used for cell polarization could drastically diminished the percentage of 
IFNγ-producing NK cells, suggesting a potent inhibitory effect on this important NK cell 
function exerted by soluble factors inside pleural effusions (Figure 13C). 
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DISCUSSION AND CONCLUSIONS 
Natural Killer cells are an important component of innate immune responses displaying 
the ability to destroy neoplastic cells or virus-infected cells and, on the other hand, to 
tolerate self, healthy cells. Natural Killer cell responses are not only restricted to 
cytotoxic effector mechanisms, but this class of lymphocytes also plays a crucial role in 
the production of immunoregulatory cytokines and chemokines: these soluble factors 
affect recruitment and function of other hematopoietic cells, reinforcing the role of NK 
cells as protagonists at the interface between innate and adaptive immunity [253]. 
However, the concept of "immune surveillance” exerted by the immune system could 
be subverted in the context of the tumor microenvironment [3]. The 
immunosuppressive TUMIC is involved in tumor evasion from NK cell-mediated killing 
through several cellular and metabolic factors. Immune and stromal cells, as well as the 
hypoxic stress inside the tumor microenvironment, are known to be negative 
regulators of NK cell cytotoxicity [254]. Tumor cells themselves develop several 
strategies to evade NK cell-mediated killing. In this regard, hypoxic stress through its 
ability to induce tumor resistance and to regulate the differentiation and function of 
immune-suppressive cells plays a determinant role in shaping the NK cell phenotype 
and function [255]. 
Within the tumor tissue, macrophages and other myeloid cells constitute a major 
component of the immune cell infiltrate [256]. Macrophages can recognize and kill 
cancer cells through the secretion of various cytokines and factors (M1 phenotype), but 
also, after phenotypic and functional modification by the tumor, can act in pro-
angiogenic and pro-tumor manner (M2/TAM phenotype). Thus, macrophages isolated 
from malignant pleural effusions, as well as TAMs, exhibit weak cytotoxic activity 
against tumor cells, increase their proliferative activity and may protect tumor cells 
from apoptosis [257]. It has also been shown that the percentage of CD163+ TAMs 
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(CD163 is a marker for the M2 macrophage phenotype [258]) in malignant PE was 
higher than that found in non-malignant pleural effusion. CD163+ TAMs in malignant 
PE patients is a prognostic factor for progression-free survival and M2-related cytokines 
were more expressed in malignant PE-derived CD163+ TAMs than in malignant PE-
derived CD163- macrophages [259]. In addition, it was demonstrated that CD163+ 
CD14+ macrophages could be used as an immune diagnostic marker for malignant PE 
[260]. 
It was also found that, regarding soluble factors present in malignant PE, the amount 
of TGFβ is higher than in PB. TGFβ is mainly produced by TAMs in malignant PE, plays 
an important role in impaired T cell cytotoxicity and in vitro treatment with anti-TGFβ 
antibody restored the impaired T cell cytotoxic activity in malignant PE [240]. 
In the solid tumor microenvironment, macrophage-derived TGFβ is able to exert an 
immunosuppressive action on NK cells, combined with expression of adenosine A2A 
receptor, that can suppress NK cell responses [261]. 
TGFβ is also involved in NK cell inhibition mediated by Treg cells [262] and dendritic 
cells [263]. Furthermore, NK cell activity was found to be inversely correlated with 
MDSC expansion. In addition, MDSC-mediated inhibition of NK cells was found to be 
cell contact dependent via membrane-bound transforming growth factor-β (TGFβ) on 
MDSC or inhibition of perforin and signal transducer and activator of transcription 5 
(Stat5) activity in NK cells [264, 265]. 
In this work, our specific interest is focused on Natural Killer cells, characterized by CD3- 
CD56+ expression and further divided depending on the density of CD56 surface 
molecule expression and based on the presence or absence of activating receptor CD16 
[142]. 
Lung tissues are moderately rich in Natural Killer cells [223, 226] and it was found that 
the predominant subset in normal parenchyma is the CD56dim CD16+ phenotype [216, 
226, 266]. NK cells infiltrating non-small cell lung cancer (NSCLC), if compared to 
autologous Natural Killer cells isolated from peripheral blood and peri-tumor lung 
tissues, are predominantly CD56bright CD16- [216, 226]. A similar phenotype has been 
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observed at the level of Natural Killer cells infiltrating breast cancer [267] and in the 
case of colorectal cancer [268]. In the present work, it was demonstrated that a similar 
pattern, characterized by abundance of poorly cytotoxic Natural Killer cells, was finally 
observed at the level of different types of pleural effusions. 
We have analyzed Natural Killer cells isolated from patients with pleural effusions 
caused by inflammatory diseases or primary or metastatic tumors of different origins. 
It has been shown that NK cells isolated from all types of pleural effusions analyzed are 
characterized by an expansion of CD56bright CD16- NK cell subset, compared to NK 
cells isolated from autologous peripheral blood or peripheral blood of healthy donors, 
in which CD56dim CD16+ cytotoxic NK cells prevail. 
Our investigation analyzing NK cell functions would indicate that cytotoxic NK cells can 
be strongly conditioned by tumor microenvironment of patients with pleural effusion 
and become cells involved in the genesis of new tumor vasculature. Taking into 
consideration the pro-angiogenic properties of Natural Killer cells it is important to 
clarify that at the level of developing decidua, in the first trimester of pregnancy, 
Natural Killer cells are converted from "killers" to "builders" [269]. Specifically, the 
CD56superbright CD16- Natural Killer cell subset forms the human immune element 
that predominates in the first trimester of pregnancy [270]. Once the embryo is 
anchored at the level of the uterine mucosa, a crucial event for the correct formation 
of fetus-mother interface is the ability of the embryo to adopt an invasive phenotype 
to induce a vascular remodeling, two crucial steps for the growth of the placenta [271, 
272]. dNK cells display an important regulatory role in the placenta development 
processes during pregnancy: purified dNK cells can produce angiogenic factors such as 
VEGF, PlGF and IL-8 [225]. 
The present work demonstrates that PE-NK cells display an increased expression of 
CD49a decidual NK cell surface marker, were poorly mature (low expression of CD57) 
and yet activated (high expression CD69). NK cells from PE display a higher amount of 
intracellular VEGF if compared to healthy and autologous PB-NK cells; this difference is 
accentuated in tmPE, in which NK cells are predominantly VEGF+, thus pro-angiogenic 
DISCUSSION AND CONCLUSIONS  
 
53 
NK cells. These data, derived from intracellular cytokine staining, are confirmed by an 
in vitro vessel formation assay (Figure 8) that reveals an important ability of tmPE-NK 
cells to induce capillary like structures on HUVECs. 
The results obtained by performing cytotoxicity assays ex vivo and the phenotypic 
analysis of the marker CD69 lead us to hypothesize that the concept of Natural Killer 
cell activation that probably not only includes the establishment of a mechanism of 
cytotoxicity because of the interaction with the appropriate target, but can also be the 
response to different nature stimuli produced by other TUMIC resident cells. These 
phenomena could justify the partial activation and the poor cytotoxicity of analyzed NK 
cells isolated from pleural effusion samples. We can consequently assume that, for the 
full activation of NK cells, more activatory stimuli are needed. 
Unexpected data obtained in this study is the concept that Natural Killer cells isolated 
from inflammatory pleural effusion exhibit features very like those obtained from the 
two type of malignant pleural effusions analyzed: it may be interesting to examine in 
depth, in future experiments, the role of Natural Killer cells in this kind of environment, 
to establish if they differ in some characteristics to those found when in a TUMIC. 
NK cells Isolated from buffy coats from healthy donors, after 7-day culture with IL-15 + 
PE, appear to increase CD56bright CD16- subsets and VEGF production. Moreover, PE 
supernatants can induce a decreased production of IFNγ. It is known that the IFNγ 
produced by Natural Killer cells can enhance the microbicidal activity of macrophages 
and promote the differentiation of lymphocytes into Th1-subtype to ensure an 
effective adaptive response against tumors [273]. In a recent study the levels of 
cytokines, chemokines and angiogenic proteins from human malignant pleural 
effusions were analyzed demonstrating a presence of an up-regulation of pro-
angiogenic proteins in malignant pleural effusions analyzed in comparison of those not 
malignant [239]. If this trend will be validated for our clinical cases, it would confirm 
the effectiveness of using an anti-angiogenic therapy in the treatment of malignant 
pleural effusions. 
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These data reinforce the idea to use the immune system as a weapon to fight tumors. 
If in the tumor microenvironment a change in normal immune protective functions 
occurs, it becomes indispensable to develop drugs that, coupled to the conventional 
chemotherapy/radiotherapy, could re-switch the anti-tumor cytotoxic function of NK 
cell. On the other hand, a good target for cancer immune therapy must be necessarily 
the inhibition of tumor angiogenic process to limit the formation of blood vessels that 
contribute to tumor progression. 
As reported by Carrega P. and colleagues, the fact that different human cancers show 
a lymphocytic infiltrate enriched in non-cytotoxic CD56bright NK cells may represent 
immunoediting process orchestrated by tumor that leads to a defective immune 
surveillance [216]. Therefore, immuno-therapies based on Natural Killer cells could be 
discovered looking at factors that induce CD56bright NK cells to differentiate, in vivo, 
into CD56dim NK cells, or factors that increase the cytotoxic NK cell chemo attraction 
to the tumor. 
Vacca et al. demonstrated that, upon culture in IL-2, PE-NK cells acquired a potent 
cytolytic activity against both allogeneic and autologous tumor cells and thus, they are 
not functionally impaired. They conclude that a short-term IL-2 activation may offer 
important clues for the development of novel approaches in tumor immunotherapy 
[274]. In the present work, we have confirmed that IL-2 can restore cytotoxicity of PE-
NK cells, but if these cells are cultured in a medium containing IL-2 along with TGFβ or 
autologous PE, this benefic action of IL-2 diminished significantly. This phenomenon 
suggests that in PE there are soluble factors present able to contrast the action of IL-2 
and to maintain NK cells in a non-cytotoxic condition and in a pro-tumor and anti-
inflammatory state. Therefore, it will be of great interest to characterize the soluble 
factors present in tumor pleural fluids and to estimate the amount of TGFβ. To evaluate 
the role of TGFβ in the counteracting the action of IL-2 treatment or in the process of 
NK cells pro-tumor polarization it will be appropriate to neutralize it with anti-TGFβ 
antibodies. A similar strategy might help, in future, to develop a therapy able to make 
NK cells permanently cytotoxic despite the TUMIC stimuli. 
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Furthermore, recent reports have shown that, in some situations, activated NK cells 
can express programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte 
associated antigen 4 (CTLA-4), two immunosuppressive surface molecules, which are 
the target of currently investigated cancer immunotherapeutic drugs (Ipilimumab 
against CTLA-4 and Nivolumab and Pembrolizumab against PD-1) that restore T cell 
activation [275, 276]. These data may suggest that an immunotherapeutic strategy 
using this type of molecules could be designed also for modulation of anti-tumor 
functionality of Natural Killer cells in the context of tumor pleural effusions. In 
conclusion, we think that a better understanding of Natural Killer cell behavior could 
be an important checkpoint for innovative immunotherapeutic approaches for primary 
or metastatic tumors presenting pleural effusion-associated condition. 
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LEGENDS OF TABLES AND FIGURES 
Table 1. 
Characteristics of all healthy controls and patients with pleural effusion analyzed 
(n=77). Healthy Controls (h): n=14 (M: n=8; F: n=6); age: mean±SEM=58,1±3,4. 
Inflammatory Pleural Effusions (iPE): n=18 (M: n=16; F: n=2); age: mean±SEM=72,2±2,2. 
Malignant Pleural Effusions from Primary Tumors (ptPE): n=18 (M: n=9; F: n=9); age: 
mean±SEM=72,8±2,5. Malignant Pleural Effusions from Tumor Metastasis (tmPE): n=27 
(M: n=11; F: n=16); age: mean±SEM=68,7±2,4. 
 
Figure 1. 
Representative dot plots that underlines CD56bright CD16- NK cells population, ex vivo, 
in peripheral blood samples of healthy individuals (hPB) (A), peripheral blood and 
pleural effusion from patients with inflammatory disease (iPB and iPE) (B), peripheral 
blood and pleural effusion from patients with primary tumor (ptPB and ptPE) (C) and 




Comparative analysis of the percentage of NK cells (within total lymphocytes) found, 
ex vivo, in peripheral blood samples of healthy individuals (hPB), peripheral blood and 
pleural effusion from patients with inflammatory disease (iPB and iPE), peripheral 
blood and pleural effusion from patients with primary tumor (ptPB and ptPE) and 
peripheral blood and pleural effusion from patients with tumor metastasis (tmPB and 
tmPE) (A). Percentage of CD56bright CD16- NK cells (B). Percentage of CD56bright and 
CD16- NK cells separately (C-D). The data are represented as mean±SEM of 64 samples 
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Comparative analysis of the percentage, evaluated ex vivo, of NK cells CD9+ (A) and 
relative MFI (B) and CD49a+ (C) and relative MFI (D) found in peripheral blood samples 
of healthy individuals (hPB), peripheral blood and pleural effusion from patients with 
inflammatory disease (iPB and iPE), peripheral blood and pleural effusion from patients 
with primary tumor (ptPB and ptPE) and peripheral blood and pleural effusion from 
patients with tumor metastasis (tmPB and tmPE). Data are shown as mean±SEM of 39 
samples (hPB: n=7; iPB/PE: n=9; ptPB/PE: n=11; tmPB/PE: n=12). * p <.05, ** p <.01. 
 
Figure 4. 
Ex vivo comparative analysis of the percentage of NK cells CD57+ (A) and relative MFI 
(B) and CD69a (C) and relative MFI (D) found in peripheral blood samples of healthy 
individuals (hPB), peripheral blood and pleural effusion from patients with 
inflammatory disease (iPB and iPE), peripheral blood and pleural effusion from patients 
with primary tumor (ptPB and ptPE) and peripheral blood and pleural effusion from 
patients with tumor metastasis (tmPB and tmPE). Data are shown as mean±SEM of 37 
samples (hPB: n=7; iPB/PE: n=9; ptPB/PE: n=11; tmPB/PE: n=10). * p <.05, ** p <.01. 
 
Figure 5. 
Comparative ex vivo analysis of the percentage of NK cells, displaying NKp30 (A) and 
NKG2D (B) activating receptor and NKG2A inhibitory receptor (C) found in peripheral 
blood samples of healthy individuals (hPB), peripheral blood and pleural effusion from 
patients with inflammatory disease (iPB and iPE), peripheral blood and pleural effusion 
from patients with primary tumor (ptPB and ptPE) and peripheral blood and pleural 
effusion from patients with tumor metastasis (tmPB and tmPE). Data are shown as 
mean±SEM of 18 samples (hPB: n=4; iPB/PE: n=4; ptPB/PE: n=5; tmPB/PE: n=5). 





Spontaneous VEGF and CXCL12/SDF-1 ex vivo production was evaluated after 1h-
incubation with monensin (2mM, BD). Comparative analysis of the percentage of NK 
cells producing VEGF (A) and CXCL12/SDF-1 (B) found in peripheral blood samples of 
healthy individuals (hPB), peripheral blood and pleural effusion from patients with 
inflammatory disease (iPB and iPE), peripheral blood and pleural effusion from patients 
with primary tumor (ptPB and ptPE) and peripheral blood and pleural effusion from 
patients with tumor metastasis (tmPB and tmPE). Data are shown as mean±SEM of 34 
samples (hPB: n=6; iPB/PE: n=8; ptPB/PE: n=10; tmPB/PE: n=10). ** p <.01. 
 
Figure 7. 
Analysis of the capacity of pleural effusion fluid from patients with inflammatory 
disease (iPE), primary tumor (ptPE) and tumor metastasis (tmPE) to induce endothelial 
cell capillary-like morphogenesis on HUVECs, after 6 hours of incubation on matrigel. 
Negative and positive controls (CTRL- and CTRL+) were obtained using a serum-free 
medium and a medium containing 10% of FBS, respectively (A). Total master segments 
length (sum of the length of the detected master segments in the analyzed area) (B) 
and Nb meshes (number of meshes in the analyzed area) (C) are evaluated with ImageJ 
software and Angiogenesis Analyzer Tool. 
 
Figure 8. 
Analysis of the capacity of NK cell supernatant to induce endothelial cell capillary-like 
morphogenesis on HUVECs, after 6 hours of incubation on Matrigel. Supernatants are 
obtained from NK cells isolated from peripheral blood and pleural effusion from 
patients with inflammatory disease (iPB and iPE), peripheral blood and pleural effusion 
from patients with primary tumor (ptPB and ptPE) and peripheral blood and pleural 
effusion from patients with tumor metastasis (tmPB and tmPE), after 6 hours of 
incubation in a serum-free RPMI medium. Negative and positive controls (CTRL- and 
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CTRL+) were obtained using a serum-free medium and a medium containing 10% of 
FBS, respectively (A). Total master segments length (sum of the length of the detected 
master segments in the analyzed area) (B) and Nb meshes (number of meshes in the 
analyzed area) (C) are evaluated with ImageJ software and Angiogenesis Analyzer Tool. 
 
Figure 9. 
Spontaneous perforin ex vivo production was evaluated after 1h-incubation with 
monensin (2mM, BD). Comparative analysis of the percentage of CD56dim CD16+ NK 
cells producing Perforin (A) and relative MFI (B) found in peripheral blood samples of 
healthy individuals (hPB), peripheral blood and pleural effusion from patients with 
inflammatory disease (iPB and iPE), peripheral blood and pleural effusion from patients 
with primary tumor (ptPB and ptPE) and peripheral blood and pleural effusion from 
patients with tumor metastasis (tmPB and tmPE). Data are shown as mean±SEM of 34 
samples (hPB: n=6; iPB/PE: n=8; ptPB/PE: n=10; tmPB/PE: n=10). * p < .05, ** p <.01. 
 
Figure 10. 
Ex vivo analysis of CD56dim CD16+ CD107a+ NK cells after 4h in vitro stimulation with 
the human erythroleukemia K562 tumor cell line target. Comparative analysis of the 
percentage of CD56dim CD16+ cytotoxic NK cells that express CD107a surface marker 
(A) and relative MFI (B) found in peripheral blood samples of healthy individuals (hPB), 
peripheral blood and pleural effusion from patients with inflammatory disease (iPB and 
iPE), peripheral blood and pleural effusion from patients with primary tumor (ptPB and 
ptPE) and peripheral blood and pleural effusion from patients with tumor metastasis 
(tmPB and tmPE). Data are shown as mean±SEM of 38 samples (hPB: n=6; iPB/PE: n=10; 
ptPB/PE: n=11; tmPB/PE: n=11). * p <.05, ** p <.01, ***p < .001. 
 
Figure 11. 
Analysis of CD56dim CD16+ CD107a+ NK cells after 4h in vitro stimulation with the 
human erythroleukemia K562 tumor cell line target, ex vivo and after 3-day in vitro 
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treatment with IL-2 (100 U/ml), IL-2+TGFβ (10 ng/ml) and IL-2+autologous PE (33% of 
culture media). CD56dim CD16+ CD107a+ NK cells from A: patients with inflammatory 
diseases; B: patients with primary tumors; C: patients with tumor metastasis. D: 
CD56dim CD16+ CD107a+ NK cells from healthy donors, ex vivo and after 3-day in vitro 
treatment with IL-2 (100 U/ml), IL-2+TGFβ (10 ng/ml) and IL-2+iPE, IL-2+ptPE and IL-
2+tmPE (PE: 33% of culture media). Data are shown as mean±SEM of 38 samples (hPB: 
n=6; iPB/PE: n=10; ptPB/PE: n=11; tmPB/PE: n=11). * p <.05, ** p <.01, ***p < .001. 
 
Figure 12. 
Comparative analysis of the percentage of CD56bright CD16- NK cells (A) on total NK 
cells purified from 13 buffy coats of healthy donors and treated for 7 days with IL-15 
(10 ng/ml), IL-15 with pleural effusion from patients with inflammatory disease (IL-
15+iPE), IL-15 with pleural effusion from patients with primary tumor (IL-15+ptPE) and 
IL-15 with pleural effusion from patients with tumor metastasis (IL-15+tmPE). Each kind 
of PE used is a pool of 10 supernatants derived from 10 different patients and it is 
placed in the culture medium not diluted, constituting the 33% of culture media. 
Percentage of CD56bright and CD16- NK cells separately (C-D). The data are 
represented as mean±SEM of 13 buffy coat samples treated with different pool of PE 
supernatants (IL-15: n=13; IL-15+iPE: n=13; IL-15+ptPE: n=13; IL-15+tmPE: n=13).  




Comparative analysis of MFI of VEGF produced by NK cells (A) from buffy coats of 
healthy donors treated for 7 days with IL-15 (10 ng/ml), IL-15 with pleural effusion from 
patients with inflammatory disease (IL-15+iPE), IL-15 with pleural effusion from 
patients with primary tumor (IL-15+ptPE) and IL-15 with pleural effusion from patients 
with tumor metastasis (IL-15+tmPE) (A). IL-15 was used at the concentration of 10 
ng/ml and the pool of PE supernatants constituted the 33% of the culture media. 
Percentage of CXCL12/SDF-1+ (B) and IFNγ+ (C) NK cells with same treatments. The data 
are represented as mean±SEM of 13 buffy coat samples (IL-15: n=13; IL-15+iPE: n=13; 
IL-15+ptPE: n=13; IL-15+tmPE: n=13). * p < .05, ** p <.01. 
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